Evidence map›Paper›PMID 31966835›Full record

ArticleInternational journal of clinical and experimental pathology2017

Genetic mutations in lung enteric adenocarcinoma identified using next-generation sequencing.

Li Lin, Wu Zhuang, Wenxian Wang, Chunwei Xu, Rongrong Chen, Yanfang Guan, Xin Yi, Yun Shao, Yanhong Tai, Yanping Chen and 3 more

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. DNA methylation profiling reliably distinguishes pulmonary enteric adenocarcinoma from metastatic colorectal cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Li LinDepartment of Oncology, Peking University International Hospital Beijing 102206, People's Republic of China.
Wu ZhuangDepartment of Medical Thoracic Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital Fujian 350014, Fuzhou, People's Republic of China.
Wenxian WangDepartment of Chemotherapy, Zhejiang Cancer Hospital Hangzhou 310022, Zhejiang, People's Republic of China.
Chunwei XuDepartment of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital Fujian 350014, Fuzhou, People's Republic of China.
Rongrong ChenGeneplus-Beijing Beijing 102200, People's Republic of China.
Yanfang GuanGeneplus-Beijing Beijing 102200, People's Republic of China.
Xin YiGeneplus-Beijing Beijing 102200, People's Republic of China.
Yun ShaoDepartment of Pathology, Affiliated Hospital Cancer Center, Academy of Military Medical Sciences Beijing 100071, People's Republic of China.
Yanhong TaiDepartment of Pathology, Affiliated Hospital Cancer Center, Academy of Military Medical Sciences Beijing 100071, People's Republic of China.
Yanping ChenDepartment of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital Fujian 350014, Fuzhou, People's Republic of China.
Meijuan WuDepartment of Pathology, Zhejiang Cancer Hospital Hangzhou 310022, Zhejiang, People's Republic of China.
Jianguo WeiDepartment of Pathology, Shaoxing People's Hospital Shaoxing 312000, Zhejiang, People's Republic of China.
Gang ChenDepartment of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital Fujian 350014, Fuzhou, People's Republic of China.
Fujian Medical University · CNState Council of the People's Republic of China · CNAcademy of Military Medical Sciences · CNZhejiang Cancer Hospital · CNPeking University · CNShaoxing People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary lung enteric adenocarcinoma is a rare type of invasive lung carcinoma. Its morphological and immunohistochemical characteristics are similar to those of metastatic colorectal carcinoma, but there is no associated primary colorectal carcinoma. The purpose of this study is to identify mutations by assessing the genetic profile of lung enteric adenocarcinoma with next-generation sequencing (NGS). This study included 11 lung enteric adenocarcinoma patients (5 males and 6 females) from three different centers who received treatment between Feb 2013 and Dec 2016. Immunohistochemical analysis failed to reveal any markers that differentiated this carcinoma from primary gastrointestinal adenocarcinoma. NGS analysis identified

Indexed as

ALKgene mutationLung enteric adenocarcinomaMSH2MSH6ROS1

Identifiers

PMID31966835
PMCPMC6966000
OpenAlexW3026396069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.